FRESENIUS MEDICAL CARE-ADR (FMS) Forecast, Price Target & Analyst Ratings
NYSE:FMS • US3580291066
22.95 USD
-0.1 (-0.43%)
At close: Mar 6, 2026
23 USD
+0.05 (+0.22%)
After Hours: 3/6/2026, 8:19:05 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for FRESENIUS MEDICAL CARE-ADR (FMS).
Forecast Snapshot
Consensus Price Target
$27.20
+ 18.53% Upside
Next Earnings Forecast
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate€0.40
Revenue Estimate4.784B
ChartMill Buy Consensus
65.93%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$27.20
Upside
+ 18.53%
From current price of $22.95 to mean target of $27.20, Based on 27 analyst forecasts
Low
$13.31
Median
$28.48
High
$38.68
Price Target Revisions
1 Month
-2.48%
3 Months
-2.87%
Price Target Summary
27 analysts have analysed FMS and the average price target is 27.2 USD. This implies a price increase of 18.53% is expected in the next year compared to the current price of 22.95.
The average price target has been revised downward by 2.87% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
65.93%
FMS was analyzed by 27 analysts. The buy percentage consensus is at 66. So analysts seem to be have mildly positive about FMS.
In the previous month the buy percentage consensus was at a similar level.
FMS was analyzed by 27 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-02 | UBS | Downgrade | Neutral -> Sell |
| 2025-05-12 | Truist Securities | Maintains | Hold -> Hold |
| 2025-01-06 | Truist Securities | Maintains | Hold -> Hold |
| 2024-10-07 | Truist Securities | Maintains | Hold -> Hold |
| 2024-07-31 | Truist Securities | Maintains | Hold -> Hold |
| 2024-05-15 | Truist Securities | Maintains | Hold -> Hold |
| 2023-11-24 | HSBC | Upgrade | Reduce -> Hold |
| 2023-10-11 | Truist Securities | Maintains | Hold -> Hold |
| 2023-07-13 | Truist Securities | Maintains | Hold -> Hold |
| 2023-05-10 | Truist Securities | Maintains | Hold -> Hold |
| 2023-04-13 | Truist Securities | Maintains | Hold |
| 2023-02-23 | Truist Securities | Maintains | Hold |
| 2022-06-22 | Truist Securities | Maintains | Hold |
| 2021-11-23 | HSBC | Initiate | Hold |
| 2021-11-17 | RBC Capital | Maintains | Sector Perform |
| 2021-11-11 | Jefferies | Upgrade | Underperform -> Hold |
| 2021-08-11 | JPMorgan Chase | Initiate | |
| 2021-08-06 | Goldman Sachs | Initiate | |
| 2021-07-24 | Jefferies | Initiate | |
| 2021-07-23 | Jefferies | Initiate | |
| 2021-07-22 | Goldman Sachs | Initiate | |
| 2021-07-21 | Goldman Sachs | Initiate | |
| 2021-07-20 | JPMorgan Chase | Initiate | |
| 2021-07-20 | Berenberg Bank | Initiate | |
| 2021-07-14 | Morgan Stanley | Initiate |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate€0.40
Revenue Estimate4.784B
Revenue Q2Q-1.99%
EPS Q2Q-1.24%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
0.31%
Revenue (3 Months)
0.62%
EPS (1 Month)
12.25%
EPS (3 Months)
14.55%
Next Earnings Summary
FMS is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is 0.4 USD and the consensus revenue estimate is 4.78B USD.
The next earnings revenue estimate has been revised upward by 0.62% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 19.454B 0.29% | 19.336B -0.61% | 19.628B 1.51% | 19.905B 1.41% | 20.724B 4.11% | 21.363B 3.08% | 22.651B 6.03% | 23.679B 4.54% | 24.707B 4.34% | 25.66B 3.86% | 26.63B 3.78% | |
| EBITDA YoY % growth | 3.03B -3.03% | 3.008B -0.73% | 3.266B 8.57% | 3.608B 10.47% | 3.815B 5.74% | 4.015B 5.24% | 4.185B 4.23% | 4.271B 2.05% | 4.962B 16.18% | 5.14B 3.59% | 5.322B 3.54% | |
| EBIT YoY % growth | 1.278B -0.65% | 1.266B -0.97% | 1.766B 39.46% | 2.16B 22.34% | 2.389B 10.60% | 2.822B 18.12% | 2.977B 5.49% | 3.203B 7.59% | 3.537B 10.43% | 3.676B 3.93% | 3.82B 3.92% | |
| Operating Margin | 6.57% | 6.55% | 9.00% | 10.85% | 11.53% | 13.21% | 13.14% | 13.53% | 14.32% | 14.33% | 14.34% | |
| EPS YoY % growth | 1.25 -17.23% | 1.58 26.66% | 2.09 32.00% | 1.95 -6.53% | 2.18 11.46% | 2.54 16.58% | 2.89 14.03% | 3.22 11.24% | 3.29 2.27% | 3.54 7.49% | 3.76 6.15% |
All data in EUR
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.40 -1.24% | 0.42 -4.52% | 0.43 -19.66% | 0.37 -47.40% |
| Revenue Q2Q % growth | 4.784B -1.99% | 4.851B 1.23% | 5.124B 4.89% | 5.299B 4.52% |
| EBITDA Q2Q % growth | 860.07M 14.42% | 901.81M -21.96% | 984.25M -37.62% | 1.042B -49.71% |
| EBIT Q2Q % growth | 473.16M 32.43% | 499.01M 29.31% | 568.13M 26.00% | 668.62M 17.01% |
All data in EUR
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
6.69%
EPS Next 5 Year
9.03%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
2.64%
Revenue Next 5 Year
3.69%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
24.27%
EBIT Next 5 Year
15.34%
FRESENIUS MEDICAL CARE-ADR / FMS Forecast FAQ
What is the price target for FMS stock?
27 analysts have analysed FMS and the average price target is 27.2 USD. This implies a price increase of 18.53% is expected in the next year compared to the current price of 22.95.
Can you provide the upcoming earnings date for FRESENIUS MEDICAL CARE-ADR?
FRESENIUS MEDICAL CARE-ADR (FMS) will report earnings on 2026-05-05.
What are the consensus estimates for FMS stock next earnings?
The consensus EPS estimate for the next earnings of FRESENIUS MEDICAL CARE-ADR (FMS) is 0.4 USD and the consensus revenue estimate is 4.78B USD.
What is the consensus rating for FMS stock?
The consensus rating for FRESENIUS MEDICAL CARE-ADR (FMS) is 65.9259 / 100 . This indicates that analysts generally have a neutral outlook on the stock.